Dendreon

File:Dendreon logo.png

Dendreon logo

Dendreon Corporation is a biotechnology company focused on the discovery, development, and commercialization of novel therapies for the treatment of cancer. The company is best known for its development of sipuleucel-T, marketed under the trade name Provenge, which is an autologous cellular immunotherapy for the treatment of prostate cancer.

History

Dendreon was founded in 1992 and is headquartered in Seattle, Washington. The company was initially focused on the development of dendritic cell-based therapies, which led to the creation of Provenge. In 2011, Provenge became the first FDA-approved immunotherapy for prostate cancer.

Products

Provenge

Provenge (sipuleucel-T) is an autologous cellular immunotherapy designed to stimulate an immune response against prostate cancer. It involves collecting a patient's own immune cells, modifying them to target prostate cancer cells, and then re-infusing them into the patient. Provenge is specifically indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer (mCRPC).

Research and Development

Dendreon has been involved in various research and development projects aimed at expanding its portfolio of cancer immunotherapies. The company has explored treatments for other types of cancer, including breast cancer and bladder cancer.

Acquisitions and Financials

In 2015, Dendreon was acquired by Valeant Pharmaceuticals International, Inc., which later became Bausch Health Companies Inc.. The acquisition was part of Valeant's strategy to expand its oncology portfolio.

See Also

• Immunotherapy
• Cancer treatment
• Biotechnology
• Prostate cancer